Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+15.6%
5Y CAGR+44.6%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+15.6%/yr
Annual compound
5Y CAGR
+44.6%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
6.3x
Strong expansion
Streak
6 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$173.70M+16.9%
2024$148.61M+8.4%
2023$137.09M+22.0%
2022$112.38M+54.2%
2021$72.88M+165.3%
2020$27.47M+243.7%
2019$7.99M-